H. Mugerwa

发表

High Prevalence of tuberculosis infection among medical students in Makerere University, Kampala: results of a cross sectional study

D. Byarugaba, A. Katamba, J. Kalyango, 2013, Archives of Public Health.

Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial.

P. Kaleebu, A. Siika, B. Castelnuovo, 2022, The lancet. HIV.

Predictors of failure on second-line antiretroviral therapy with protease inhibitor mutations in Uganda

F. Kiweewa, Mary Nakafeero, D. Serwadda, 2021, AIDS Research and Therapy.

Performance of Frontloading for Smear Microscopy in the Diagnosis of Pulmonary Tuberculosis: A Cross-Sectional Study at a Referral Hospital in Uganda

W. Worodria, J. Kalyango, B. Asiimwe, 2012, PloS one.

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

P. Easterbrook, H. Namata, A. Siika, 2018, The Lancet. Infectious diseases.

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial

P. Easterbrook, T. Peto, N. French, 2017, The lancet. HIV.

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

Rebecca M. Baker, Phuong Thi Tuyet Nguyen, Carol L. Eyler, 2021, The Lancet Infectious Diseases.

Predictors of failure on second-line antiretroviral therapy with protease inhibitor mutations in Uganda

F. Kiweewa, Mary Nakafeero, D. Serwadda, 2020, AIDS Research and Therapy.

Ethical and practical considerations in HIV drug trial closure: perspectives of research staff in Uganda

C. Evans, K. Cox, Sylivia Nalubega, 2020, Research Ethics.

Lessons from an international trial evaluating vaccination strategies for recovered inpatients with COVID-19 (VATICO)

J. Lundgren, A. Gelijns, J. Neaton, 2022, Med.

Moving to Another World: Understanding the Impact of Clinical Trial Closure on Research Participants Living With HIV in Uganda.

C. Evans, K. Cox, Sylivia Nalubega, 2019, The Journal of the Association of Nurses in AIDS Care : JANAC.

Response to antiretroviral therapy of HIV type 1-infected children in urban and rural settings of Uganda.

F. Ssali, C. Kityo, R. Colebunders, 2012, AIDS research and human retroviruses.

Efficacy of Cipargamin (KAE609) in a Randomized, Phase II Dose-Escalation Study in Adults in Sub-Saharan Africa With Uncomplicated Plasmodium falciparum Malaria

Kwaku Poku Asante, E. Karita, A. Oduro, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Perceptions of HIV Self-Management Roles and Challenges in Adolescents, Caregivers, and Health Care Providers.

R. Stephenson, M. Mutumba, V. Musiime, 2018, The Journal of the Association of Nurses in AIDS Care : JANAC.

Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV.

A. Siika, B. Castelnuovo, A. Kiragga, 2021, The New England journal of medicine.

Factors associated with virological non-suppression among HIV-positive children receiving antiretroviral therapy at the Joint Clinical Research Centre in Lubowa, Kampala Uganda

J. Matovu, F. Makumbi, J. Kagaayi, 2021, PloS one.

Towards access for all: 1st Working Group Report for the Global Gene Therapy Initiative (GGTI)

Umut A. Gurkan, M. Dybul, U. Gurkan, 2021, Gene Therapy.

Hepatic safety and tolerability of cipargamin (KAE609), in adult patients with Plasmodium falciparum malaria: a randomized, phase II, controlled, dose-escalation trial in sub-Saharan Africa

Kwaku Poku Asante, E. Karita, G. Kullak-Ublick, 2021, Malaria journal.

Smoking and Accelerated Lung Function Decline in HIV-Positive Individuals: A Secondary Analysis of the START Pulmonary Substudy

A. Melzer, K. Crothers, M. Ristola, 2018, Journal of acquired immune deficiency syndromes.

Prevalence of non-communicable diseases among HIV positive patients on antiretroviral therapy at joint clinical research centre, Lubowa, Uganda

H. Mugerwa, D. Mwesigire, Sheila Kansiime, 2019, PloS one.

Urine Lipoarabinomannan Testing in Adults With Advanced Human Immunodeficiency Virus in a Trial of Empiric Tuberculosis Therapy

Y. Manabe, M. Hosseinipour, J. Kumwenda, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial

P. Easterbrook, N. French, H. Namata, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Facilitated transition in HIV drug trial closure: A conceptual model for HIV post-trial care

C. Evans, K. Cox, Sylivia Nalubega, 2020, PloS one.

RELIABILITY AND VALIDITY OF SUBJECTIVE ASSESSMENT OF LUMBAR LORDOSIS IN CONVENTIONAL RADIOGRAPHY.

H. Mugerwa, R. Byanyima, E. Ruhinda, 2014, East African medical journal.

Antiretroviral Initiation at ≥800 CD4+ Cells/mm3 Associated With Lower Human Immunodeficiency Virus Reservoir Size

Christina C. Chang, S. Lewin, M. Vjecha, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Perceptions of HIV Self-Management Roles and Challenges in Adolescents, Caregivers, and Health Care Providers.

R. Stephenson, M. Mutumba, V. Musiime, 2018, The Journal of the Association of Nurses in AIDS Care : JANAC.

Perceptions of Strategies and Intervention Approaches for HIV Self-Management among Ugandan Adolescents: A Qualitative Study

R. Stephenson, M. Mutumba, V. Musiime, 2019, Journal of the International Association of Providers of AIDS Care.

Pneumoproteins and biomarkers of inflammation and coagulation do not predict rapid lung function decline in people living with HIV

T. Harrer, A. Winston, E. Harrer, 2023, Scientific Reports.

Risk factors for antiretroviral therapy (ART) discontinuation in a large multinational trial of early ART initiators.

S. Cole, A. Phillips, J. Lundgren, 2019, AIDS (London).

Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial.

C. Kityo, N. Paton, K. Chew, 2023, The Lancet. Infectious diseases.

Urine Lipoarabinomannan Testing in Adults With Advanced Human Immunodeficiency Virus in a Trial of Empiric Tuberculosis Therapy

Y. Manabe, M. Hosseinipour, J. Kumwenda, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial.

V. van Eygen, I. Mambule, J. Musaazi, 2024, The Lancet. Infectious diseases.